Ryan Mercer Phones & Addresses
-
Dripping Springs, TX
-
San Jose, CA
-
Santa Clara, CA
-
Burleson, TX
-
Glendale, AZ
-
Phoenix, AZ
-
Peoria, AZ
-
Maricopa, AZ
-
23945 N 67Th Ave, Glendale, AZ 85310 (623) 582-3500
Work
Position:
Professional/Technical
Education
Degree:
High school graduate or higher
Public records
Vehicle Records
Ryan Mercer
View pageAddress:
23945 N 67 Ave, Glendale, AZ 85310
VIN:
1GNFC16J27R222673
Make:
CHEVROLET
Model:
SUBURBAN
Year:
2007
Business Records
Name / Title
Company / Classification
Phones & Addresses
Principal
Rycom Communications Systems L
Communication Services
Communication Services
7100 W Nadine Way, Peoria, AZ 85383
Publications
Us Patents
Suspension Formulations Of Insulinotropic Peptides And Uses Thereof
View pageUS Patent:
8299025, Oct 30, 2012
Filed:
Apr 22, 2008
Appl. No.:
12/148896
Inventors:
Thomas R. Alessi - Hayward CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
Assignee:
Intarcia Therapeutics, Inc. - Hayward CA
International Classification:
A61K 38/26
A61P 3/10
A61P 3/10
US Classification:
514 72, 514 68, 514 69
Abstract:
A suspension formulation of an insulinotropic peptide (e. g. , glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents
View pageUS Patent:
8343140, Jan 1, 2013
Filed:
Feb 12, 2009
Appl. No.:
12/378341
Inventors:
Thomas R. Alessi - Hayward CA, US
Karling Alice Leung - Oakland CA, US
Ryan D. Mercer - Dublin CA, US
Cristina G. Negulescu - Santa Clara CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
Karling Alice Leung - Oakland CA, US
Ryan D. Mercer - Dublin CA, US
Cristina G. Negulescu - Santa Clara CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
Assignee:
Intarcia Therapeutics, Inc. - Hayward CA
International Classification:
A61K 9/22
US Classification:
6048921
Abstract:
The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.
Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof
View pageUS Patent:
20100092566, Apr 15, 2010
Filed:
Oct 14, 2009
Appl. No.:
12/587946
Inventors:
Thomas R. Alessi - Hayward CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
International Classification:
A61K 9/14
A61K 47/26
A61K 31/197
A61K 31/405
A61K 38/02
A61K 38/21
A61K 38/26
A61K 39/395
A61K 47/26
A61K 31/197
A61K 31/405
A61K 38/02
A61K 38/21
A61K 38/26
A61K 39/395
US Classification:
424489, 514777, 514562, 514419, 514 2, 424 854, 514 12, 4241301, 4241331, 4241351, 4241411
Abstract:
Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability.
Suspension Formulations Of Insulinotropic Peptides And Uses Thereof
View pageUS Patent:
20120178687, Jul 12, 2012
Filed:
Nov 15, 2010
Appl. No.:
12/927432
Inventors:
Thomas R. Alessi - Hayward CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
International Classification:
A61K 38/26
A61M 37/00
B23P 17/04
A61P 3/10
A61M 37/00
B23P 17/04
A61P 3/10
US Classification:
514 117, 6048921, 2989009
Abstract:
A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
Highly Concentrated Drug Particles, Formulations, Suspensions And Uses Thereof
View pageUS Patent:
20120289944, Nov 15, 2012
Filed:
Jul 7, 2012
Appl. No.:
13/543821
Inventors:
Thomas R. Alessi - Hayward CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
Assignee:
INTARCIA THERAPEUTICS, INC. - Hayward CA
International Classification:
A61M 37/00
US Classification:
6048921
Abstract:
Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability.
Devices, Formulations, And Methods For Delivery Of Multiple Beneficial Agents
View pageUS Patent:
20130090287, Apr 11, 2013
Filed:
Nov 29, 2012
Appl. No.:
13/689410
Inventors:
Thomas R. Alessi - Hayward CA, US
Karling Alice Leung - Oakland CA, US
Ryan D. Mercer - Dublin CA, US
Cristina G. Negulescu - Santa Clara CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
Karling Alice Leung - Oakland CA, US
Ryan D. Mercer - Dublin CA, US
Cristina G. Negulescu - Santa Clara CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
Assignee:
INTARCIA THERAPEUTICS, INC. - Hayward CA
International Classification:
A61K 47/32
US Classification:
514 53, 514 117, 514 72
Abstract:
The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.
Identifying An Origin Of Abnormal Driving Behavior For Improved Vehicle Operation
View pageUS Patent:
20220332324, Oct 20, 2022
Filed:
Apr 20, 2021
Appl. No.:
17/235607
Inventors:
- Plano TX, US
Ryan Mercer - Mountain View CA, US
Ryan Mercer - Mountain View CA, US
International Classification:
B60W 40/09
B60W 50/08
B60W 50/08
Abstract:
The disclosure includes embodiments for identifying an origin of abnormal driving behavior for improved vehicle operation. A method includes identifying an abnormal driving behavior of a driver of a vehicle at a time T. The method includes identifying a set of events that occurred within a predetermined time Δt before time T. The method includes executing, by a processor, a cause-and-effect analysis on the set of events to determine one or more events from the set of events that caused the abnormal driving behavior. The method includes executing a strategy to reduce the abnormal driving behavior so that vehicle operation is improved.
Method Of Manufacturing An Osmotic Delivery Device
View pageUS Patent:
20200054717, Feb 20, 2020
Filed:
Jun 14, 2019
Appl. No.:
16/441803
Inventors:
- Boston MA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
Ryan D. Mercer - Dublin CA, US
Catherine M. Rohloff - Los Altos CA, US
Bing Yang - Redwood City CA, US
International Classification:
A61K 38/26
A61K 47/32
A61K 47/26
A61K 47/20
A61K 47/12
C07K 7/06
A61K 9/70
A61K 9/00
C07K 14/605
A61K 47/14
A61K 9/16
A61K 9/10
A61K 47/32
A61K 47/26
A61K 47/20
A61K 47/12
C07K 7/06
A61K 9/70
A61K 9/00
C07K 14/605
A61K 47/14
A61K 9/16
A61K 9/10
Abstract:
A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.